RT @CochraneNursing: Compared to antipsychotic dose continuation, dose reduction increased the risk of #relapse (low certainty evidence) an…
RT @CochraneJapan: 統合失調症がある人に対する抗精神病薬の減量 https://t.co/2HJi14uGwm
RT @CochraneJapan: 統合失調症がある人に対する抗精神病薬の減量 https://t.co/2HJi14uGwm
不確実な結果もありますが、抗精神病薬の減量は生活の質や再入院にはあまり関連がなさそうです。平均的な効果の話ですので、全ての人に当てはまるわけではありません。
RT @CochraneJapan: 統合失調症がある人に対する抗精神病薬の減量 https://t.co/2HJi14uGwm
統合失調症がある人に対する抗精神病薬の減量 https://t.co/2HJi14uGwm
RT @CochraneFrance: 🗓️Journées de la Schizophrénie 📚Retour sur 4 résumés @CochraneSchFIN évaluant différents médicaments et interventions p…
🗓️Journées de la Schizophrénie 📚Retour sur 4 résumés @CochraneSchFIN évaluant différents médicaments et interventions pour la Schizophrénie 🔗https://t.co/mjaQ7zN0s9 🔗https://t.co/lDeQi7C7BI 🔗https://t.co/hiNfF1HK14 🔗https://t.co/q9lXS6e82D
RT @CochraneNursing: Compared to antipsychotic dose continuation, dose reduction increased the risk of #relapse (low certainty evidence) an…
RT @CochraneNursing: Compared to antipsychotic dose continuation, dose reduction increased the risk of #relapse (low certainty evidence) an…
Compared to antipsychotic dose continuation, dose reduction increased the risk of #relapse (low certainty evidence) and dropouts (moderate certainty evidence) in stable individuals with #schizophrenia. Learn more here: https://t.co/5H4dQZcFyq @CochraneLibr
少なくとも、このコクランレビューだけでは、統合失調症における抗精神病薬の減薬に積極的にはなり難いですね。 Antipsychotic dose reduction compared to dose continuation for people with schizophrenia https://t.co/Kg5JSTB8zT
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia https://t.co/Ibnk37VxLR
A new #CochraneReview assesses the efficacy and safety of reducing antipsychotic dose compared to continuing the current dose for people with #schizophrenia. The review considers #evidence from 25 studies involving a total of 2721 participants. https://t.c